DK1285080T3 - Fremgangsmåde til oprensning af alphavirusreplikonpartikler - Google Patents

Fremgangsmåde til oprensning af alphavirusreplikonpartikler

Info

Publication number
DK1285080T3
DK1285080T3 DK01941874T DK01941874T DK1285080T3 DK 1285080 T3 DK1285080 T3 DK 1285080T3 DK 01941874 T DK01941874 T DK 01941874T DK 01941874 T DK01941874 T DK 01941874T DK 1285080 T3 DK1285080 T3 DK 1285080T3
Authority
DK
Denmark
Prior art keywords
purification
alphavirus replicon
methods
replicon particles
disclosed
Prior art date
Application number
DK01941874T
Other languages
English (en)
Inventor
John M Polo
Catherine Greer
Maria Calderon-Cacia
La Vega Daniel Del Jr
Thomas W Dubensky Jr
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1285080T3 publication Critical patent/DK1285080T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Powder Metallurgy (AREA)
  • Disintegrating Or Milling (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK01941874T 2000-05-31 2001-05-31 Fremgangsmåde til oprensning af alphavirusreplikonpartikler DK1285080T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20837600P 2000-05-31 2000-05-31
PCT/US2001/018021 WO2001092552A2 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Publications (1)

Publication Number Publication Date
DK1285080T3 true DK1285080T3 (da) 2008-12-01

Family

ID=22774372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01941874T DK1285080T3 (da) 2000-05-31 2001-05-31 Fremgangsmåde til oprensning af alphavirusreplikonpartikler

Country Status (9)

Country Link
US (4) US6767699B2 (da)
EP (1) EP1285080B1 (da)
AT (1) ATE409749T1 (da)
AU (1) AU2001275191A1 (da)
CA (1) CA2410948C (da)
DE (1) DE60135983D1 (da)
DK (1) DK1285080T3 (da)
ES (1) ES2312447T3 (da)
WO (1) WO2001092552A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス,インコーポレイテッド アルファウイルスレプリコンベクター系
US7195905B2 (en) * 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
ATE427990T1 (de) 2002-04-30 2009-04-15 Oncolytics Biotech Inc Verbesserte reinigungsmethode fur viren
WO2004030631A2 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
ES2618309T3 (es) 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
DK2290054T3 (da) * 2002-12-13 2017-07-03 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling deraf
KR101454842B1 (ko) * 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US7419674B2 (en) * 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
CA2567254C (en) * 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
EP2061508B1 (en) * 2006-09-12 2014-10-15 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2008085557A2 (en) 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
DK2099485T3 (da) * 2006-11-03 2018-05-22 Alphavax Inc Alfavirus- og alfavirusreplikonpartikelformuleringer samt tilhørende fremgangsmåder
AU2008266807B2 (en) * 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
CN105056229A (zh) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
US10072307B1 (en) 2009-01-23 2018-09-11 Colorado State University Research Foundation Isolation of viruses using anionic resin beads
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
KR20150023923A (ko) 2010-07-30 2015-03-05 이엠디 밀리포어 코포레이션 크로마토그래피 매질 및 방법
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
CN105992816B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
CN106794389A (zh) 2014-09-02 2017-05-31 Emd密理博公司 具有纳米原纤化表面特征的高表面积纤维介质
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
SG11201703399QA (en) 2014-12-08 2017-05-30 Emd Millipore Corp Mixed bed ion exchange adsorber
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3393507B1 (en) 2015-12-23 2024-02-07 Valneva Austria GmbH Zika virus purification
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
NZ761619A (en) 2017-09-21 2024-03-22 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
ES8800988A1 (es) 1985-04-05 1987-12-16 Meloy Lab Procedimiento de producir interferona humana.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1988000472A1 (en) 1986-07-23 1988-01-28 Aphton Corporation Immunogens and improved methods of making immunogens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5093239A (en) 1988-05-02 1992-03-03 Eastman Kodak Company Reagents for detecting oxidase positive microorganisms
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
JPH06502311A (ja) 1990-10-22 1994-03-17 フォックス・チェイス・キャンサー・センター Rna療法を提供するためのdna構造
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
DE4315109A1 (de) 1993-05-06 1994-11-10 Inst Pflanzengenetik & Kultur Verfahren und Vektorkonstrukt zur Expressionssteigerung von Transgenen
EP0647716B1 (fr) 1993-07-06 2003-09-24 Universite De Nice-Sophia Antipolis Vecteur comportant un gène viral transcrit par l'ARN polymérase III
US5837503A (en) 1993-07-07 1998-11-17 Universite De Nice-Sophia-Antipolis Vector containing viral gene transcribed by RNA polymerase III and methods for use
EP0716148B1 (en) 1993-09-15 2004-01-02 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
IL112371A0 (en) 1994-01-25 1995-03-30 Res Dev Foundation A novel protein from aedes albopictus cells and methods for its use
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
EP0847442A1 (en) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU2051297A (en) 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
WO1998013511A1 (en) 1996-09-25 1998-04-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
EP0932693A1 (en) 1996-10-10 1999-08-04 Henrik Garoff Alphavirus-retrovirus vectors
AU7637796A (en) 1996-12-09 1998-07-03 James Edwin Bailey Expression of active interferon beta 1 using recombinant rna replicons
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
EP0996737A1 (en) 1997-08-15 2000-05-03 Inex Pharmaceuticals Corp. Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
EP1034289A1 (en) 1997-11-14 2000-09-13 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
WO1999025859A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors
WO1999030734A1 (en) 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Also Published As

Publication number Publication date
AU2001275191A1 (en) 2001-12-11
WO2001092552A3 (en) 2002-05-23
ES2312447T3 (es) 2009-03-01
US6767699B2 (en) 2004-07-27
DE60135983D1 (de) 2008-11-13
CA2410948A1 (en) 2001-12-06
WO2001092552A2 (en) 2001-12-06
US20020015945A1 (en) 2002-02-07
US20050112752A1 (en) 2005-05-26
EP1285080A2 (en) 2003-02-26
US20120231526A1 (en) 2012-09-13
EP1285080B1 (en) 2008-10-01
CA2410948C (en) 2012-07-17
ATE409749T1 (de) 2008-10-15
US20100055128A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
DK1285080T3 (da) Fremgangsmåde til oprensning af alphavirusreplikonpartikler
ATE472335T1 (de) Chimere alphavirus-replikon-partikel
ATE420965T1 (de) Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
MX2019000252A (es) Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
DK1651666T3 (da) Alfavirus-baserede cytomegalovirusvacciner
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
NO964862L (no) Papillomavirusvaksiner
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
CR20210370A (es) Neoantígenos prostáticos y sus usos
MX2022014161A (es) Vacunas contra sars-cov-2.
BRPI0516576A (pt) vetores quiméricos
WO2007046839A3 (en) New live virus vaccines
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
ATE404582T1 (de) Immunogene zusammensetzungen, die replikonvektoren des venezolanischen pferdeencephalitisvirus und paramyxovirus- proteinantigene enthalten
ATE321853T1 (de) Humanische pellino-polypeptide
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
Lampe et al. Anomalous transport coefficients for HANE applications due to plasma micro-instabilities
YU16292A (sh) Novi etnomopoksvirusni ekspresioni sistem
ATE318893T1 (de) Verbesserte replikation von hcv rna
DK1594991T3 (da) Fremgangsmåde til fremstilling af DNA-molekyler
ATE263234T1 (de) Veränderte, kleine rna-viren